3D human primary liver model

Drug-induced liver injury (DILI) refers to liver damage caused by drugs and their metabolites during drug use, and is one of the most common serious adverse drug reactions and an important cause of drug clinical trial failure.

The IBAC 3D PHH model, constructed using human primary hepatocytes (PHH), is an ideal in vitro model for assessing drug hepatotoxicity, metabolic enzyme induction/inhibition and drug metabolism.

  • Liver toxicity assessment
  • Drug metabolism studies
  • Metabolic enzyme induction/inhibition studies
Sample data
Higher cell activity
Compared to the 2D PHH model, the IBAC 3D PHH model shows a higher survival rate during over 15 days, with continuous increase in viability.
Enhanced liver function
Compared to the 2D PHH model, the IBAC 3D PHH model exhibits greater bionic liver physiological function, resulting in higher production rates of albumin and urea that remain stable for up to 28 days.
Higher and more stable liver metabolic enzyme activity
The IBAC 3D PHH model showed a significantly higher expression level of the CYP450 enzyme compared to the 2D PHH model. Additionally, the enzyme activity remained stable during long-term culture in the IBAC 3D PHH model.
The positive predictive rate of drug hepatotoxicity is significantly higher than that of animal models
The positive prediction rate of liver toxicity in IBAC 3D PHH model can reach over 80%, which is 30% higher than that in animal models; Compared with other models reported in the literature, it has the highest sensitivity, reaching 71.1%. In addition, the model also has the advantages of high throughput, low cost, and high data stability.
Model Catalog